Anidulafungin

{{drugbox | IUPAC_name = N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2R)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0^9,13]heptacosan-18-yl]-4-{4-[4-(pentyloxy)phenyl]phenyl}benzamide | image = Anidulafungin.svg | width = 300px | CAS_number = 166663-25-8 | ATC_prefix = J02 | ATC_suffix = AX06 | ATC_supplemental = | PubChem = 166548 | DrugBank = APRD01301 | C=58 | H=73 | N=7 | O=17 | molecular_weight = 1140.24 g/mol | bioavailability = | protein_bound = 84% | metabolism = | elimination_half-life = 40-50 hours | pregnancy_category = | legal_status = | routes_of_administration = }} Anidulafungin or Eraxis (Ecalta in Europe) is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006 [1]; it was previously known as LY303366. There is preliminary evidence that it has a similar safety profile to caspofungin. It has proven efficacy against oesophageal candidiasis, but its main utility will probably be in invasive Candida infection; it will probably also have application in treating invasive Aspergillus infection. It is a member of the class of anti-fungal drugs known as the echinocandins: its mechanism of action is by inhibition of (1→3)β-D-glucan synthase, which is an important component of the fungal cell wall.

Pharmacokinetics

Anidulafungin significantly differs from other antifungals in that it undergoes chemical degradation to inactive forms at body pH and temperature. Because it does not rely on enzymatic degradation or hepatic or renal excretion, the drug is safe to use in patients with any degree of hepatic or renal impairment.

References

• Krause DS, Reinhardt J, Vazquez JA, Reboli A, Goldstein BP, Wible M, Henkel T (2004). "Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia". Antimicrob Agents Chemother. 48 (6): 2021–4. doi:10.1128/AAC.48.6.2021-2024.2004. PMID 15155194.{{cite journal}}: CS1 maint: multiple names: authors list (link)
• Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ (2005). "In Vitro Activities of Anidulafungin against More than 2,500 Clinical Isolates of Candida spp., Including 315 Isolates Resistant to Fluconazole". J Clin Microbiol. 43 (11): 5425–7. doi:10.1128/JCM.43.11.5425-5427.2005. PMID 16272464.{{cite journal}}: CS1 maint: multiple names: authors list (link)
• Pfaller MA, Diekema DJ, Boyken L, Messer SA, Tendolkar S, Hollis RJ, Goldstein BP (2005). "Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis". Antimicrob Agents Chemother. 49 (11): 4795–7. doi:10.1128/AAC.49.11.4795-4797.2005. PMID 16251335.{{cite journal}}: CS1 maint: multiple names: authors list (link)